About 25 results found for searched term "ACT001" (0.127 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M57989 | ACT001 | Others |
| ACT001 | ||
| M6866 | KL 001 | Others |
| KL 001 is a first-in-class cryptochrome protein (CRY) stabilizer that interacts specifically with CRY1 and CRY2 to prevent ubiquitin-dependent CRY degradation, thereby prolonging the circadian cycle. In addition, KL001 has the potential to control fasting hormone-induced gluconeogenesis. | ||
| M8699 | EPI-001 | Androgen Receptor |
| EPI001 | ||
| EPI-001 is a specific inhibitor of the AR (androgen receptor) without inhibiting PR or GR transcriptional activities. EPI-001 can inhibit transactivation of the AR amino-terminal domain (NTD), with an IC50 of ~6 μM. EPI-001 is also a selective modulator of PPARγ. | ||
| M10288 | BMS-1001 | PD-1/PD-L1 |
| BMS-1001 free base; BMS1001 | ||
| Bms-1001 Hydrochloride is orally active and is an inhibitor of the human PD-L1/PD-1 immune checkpoint. Bms-1001 Hydrochloride is characterized by low cytotoxicity.r. | ||
| M10583 | RRX-001 | NLR |
| ABDNAZ | ||
| Rrx-001 is a hypoxic selective epigenetic factor that has been used as a radiation or chemotherapy sensitizer to induce apoptosis. Rrx-001 is an immune checkpoint inhibitor that down-regulates CD47 and SIRP-α. Rrx-001 is also an effective inhibitor of G6PD with strong antimalarial activity. Rrx-001 inhibits the expression of CD47 in tumor cells by inhibiting c-myC, a positive regulator of CD47. | ||
| M10727 | Pulrodemstat benzenesulfonate | Histone demethylase |
| CC-90011 benzenesulfonate | ||
| CC-90011 (Pulrodemstat) benzenesulfonate is a potent, selective, reversible and orally active lysine-specific demethylase-1 (LSD1) inhibitor,IC50 0.25 nM. CC-90011 benzenesulfonate has less enzymatic inhibition of LSD2, MOA-A and MAO-B. CC-90011 benzenesulfonate induces differentiation of acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells and has potent anti-cancer activity. | ||
| M11043 | DJ001 | Others |
| DJ001 is a highly specific, selective and non-competitive protein tyrosine phosphatase-σ (PTPσ) inhibitor,IC50 is 1.43 μM. DJ001 has no inhibitory activity against other phosphatases and only moderate inhibitory activity against protein phosphatase 5. DJ001 Promotes hematopoietic stem cell regeneration. | ||
| M11439 | NCGC00138783 | Others |
| NCGC00138783 selectively blocked the interaction of CD47/SIRPα with IC50 of 40 μM. NCGC00138783 does not disrupt the binding of CD47/SIRPα to other receptors. | ||
| M11527 | BCH001 | DNA/RNA Synthesis |
| 3-Quinolinecarboxylic acid | ||
| BCH001 is a quinoline derivative and a selective PAPD5 inhibitor. BCH001 restores telomerase activity and telomere length in pluripotent stem cells induced by congenital keratosis (DC). BCH001 did not inhibit poly (A) -specific ribonucase (PARN) or several other polynucleotide polymerases. PAPD5 is A nonnormalized Poly (A) polymerase with an unconventional RNA binding motif. | ||
| M15016 | Recombinant Human Eotaxin-2/CCL24 (E. coli) | Cytokines and Growth Factors |
| C-C motif chemokine 24; CK-beta-6 | ||
| Recombinant human Eotaxin-2/CCL24 protein (E. coli) is a new CC chemokine recently discovered. It is produced by activated monocytes and T lymphocytes. Protein structure: CCL24 (VAL27-ALA104), Accession # : O00175. | ||
| M20780 | CC-90010 | Epigenetic Reader Domain |
| CC-90010 is a reversible, orally active and central nervous system-penetrant inhibitor of bromodomain and extra-terminal (BET) proteins. CC-90010 is applied in the study for advanced solid tumors. | ||
| M21166 | Recombinant Human IL32 (E.coli) | Cytokines and Growth Factors |
| Natural killer cells protein 4；Tumor necrosis factor alpha-inducing factor | ||
| It induces various cytokines such as TNFA/TNF-α and IL8. it activates the typical cytokine signaling pathways NF-kappa-B and p38 MAPK. accession # P24001. | ||
| M25028 | Idactamab | Others |
| INT-001 | ||
| Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5). | ||
| M27924 | GNE-900 | Checkpoint |
| GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC50s of 0.0011, 1.5 µM for ChKl, ChK2, respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis. gemcitabine and GNE-900 administration shows anti-tumor activity. | ||
| M28509 | KB130015 | Thyroid Hormone Receptor |
| KB015 | ||
| KB130015 (KB015) is an orally active and potent ThRα and ThRβ (Thyroid Hormone Receptor) inhibitor, with IC50 values of 4.5 and 5.1 μM, respectively. KB130015 has antiarrhythmic properties. KB130015 markedly slows the kinetics of inactivation of Na+ channels. KB130015 opens large-conductance Ca2+-activated K+ channels and relaxes vascular smooth muscle. | ||
| M28513 | DPM-1001 | Phosphatase |
| DPM-1001 is a potent, specific, orally active and non-competitive inhibitor of protein-tyrosine phosphatase (PTP1B) with an IC50 of 100 nM. DPM-1001 is an analog of the specific PTP1B inhibitor MSI-1436. DPM-1001 has anti-diabetic property. | ||
| M28523 | UDM-001651 | PAR |
| UDM-001651 is a potent, selective, and orally bioavailable protease-activated receptor 4 (PAR4) antagonist (IC50=4 nM; Kd=1.4 nM). UDM-001651 shows antiplatelet potency (IC50=25 nM) in a γ-thrombin-induced platelet-rich plasma aggregation assay (γ-Thr PRP). | ||
| M28645 | Azilsartan mepixetil | Angiotensin Receptor |
| Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A). | ||
| M29194 | Fosmanogepix | Antifungal |
| APX001; E1211 | ||
| Fosmanogepix (APX001) is a first-in-class and orally available broad-spectrum antifungal agent, which targets the highly conserved Gwt1 fungal enzyme. Fosmanogepix (APX001) is an N-phosphonooxymethyl precursor which is rapidly and completely metabolized by systemic alkaline phosphatases to the active moiety, APX001A. Fosmanogepix (APX001) can be used in development for the treatment of invasive fungal infections. | ||
| M29254 | BMS-1001 hydrochloride | PD-1/PD-L1 |
| BMS-1001 hydrochloride is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 hydrochloride exhibits low-toxicity in cells. | ||
| M30696 | LJ001 | Anti-infection |
| LJ001 is a broad-spectrum and orally active antiviral agent. LJ001 exerts antiviral activities by binding to viral membranes. LJ001 inhibits TGEV and PDCoV infection. LJ001 decreases TGEV N and PDCoV N-protein expression. | ||
| M30826 | EAI001 | EGFR/HER2 |
| EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer. | ||
| M30973 | (S)-BI-1001 | Others |
| (S)-BI-1001 (Compound 11) is an active S-enantiomer of BI-1001. (S)-BI-1001 exhibits antiviral potency against HIV-1 integrase with an IC50 of 28 nM, an EC50 of 450 nM and a Kd of 4.7 μM. | ||
| M31059 | DPM-1001 trihydrochloride | Phosphatase |
| DPM-1001 trihydrochloride is a potent, specific, orally active and non-competitive inhibitor of protein-tyrosine phosphatase (PTP1B) with an IC50 of 100 nM. DPM-1001 trihydrochloride is an analog of the specific PTP1B inhibitor MSI-1436. DPM-1001 trihydrochloride has anti-diabetic property. | ||
| M41574 | YCH1899 | PARP |
| YCH1899 is an orally active PARP inhibitor, with an IC50< 0.001 nM for PARP1/2. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
